Patients with metastatic breast cancer may not benefit from surgery and radiation after chemotherapy

December 11, 2013, American Association for Cancer Research

After a response to initial chemotherapy, treatment with radiotherapy and surgical removal of the breast tumor and nearby lymph nodes do not provide any additional benefit to patients with metastatic breast cancer, according to results of a clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

"There is a small percentage, about 5 to 20 percent of , who present with metastatic when they see their doctors for the first time, and across the globe, the thought is that the local tumor in such events does not require any surgery or radiation [known as loco-regional treatment (LRT)] after chemotherapy, unless there is bleeding or ulceration," said Rajendra Badwe, M.D., director of the Tata Memorial Hospital in Mumbai, India. "However, there are conflicting results from retrospective analyses, and hence, there was a need for a randomized trial.

"We found that there was no difference in overall survival between those who received LRT and those who did not receive LRT," explained Badwe. "Indeed, there was a 7 percent excess death rate in those who received LRT. This finding was not statistically significant; nevertheless, it aligns with previous preclinical findings that suggest surgical removal of the primary tumor bestows a growth advantage on metastases.

"I'm sure a lot of oncologists who believe in conventional wisdom and don't provide loco-regional treatment will feel a lot more comfortable looking at these results," said Badwe. "As for those who have changed practice based on the retrospective study history, they would have to rethink."

Badwe and colleagues conducted a prospective, randomized, controlled trial, to which they recruited 350 women between 2005 and 2013. Eligible had and an objective tumor response to six cycles of chemotherapy. Patients were randomized to two arms: 173 women received LRT (LRT arm) and 177 women received no LRT (no-LRT arm). Both arms were matched for age, clinical tumor size, and HER2 receptor status, and status of disease spread.

Patients in the LRT arm underwent partial or complete surgical removal of their breasts and surgical removal of axillary , followed by radiotherapy. Patients in the no-LRT arm did not receive any surgery or radiotherapy. Patients from both arms whose breast cancers were hormone-related received standard hormone therapy. The primary endpoint of the study was overall survival. Nine patients from the LRT arm and three patients from no-LRT arm could not adhere to trial protocol.

During the median follow-up period of 17 months, the investigators recorded 218 deaths, 111 from the LRT arm and 107 from the no-LRT arm.

They found that the median overall survival in the LRT and no-LRT arms were 18.8 months and 20.5 months, respectively. Overall survival after two years of follow-up was 40 percent in the LRT arm and 43.3 percent in the no-LRT . No difference in overall survival between the two arms emerged, even after adjusting for age, hormone receptor and HER2 receptor status, site of disease spread, and number of tumors in organs other than the indicated breast.

Explore further: Avoiding radiotherapy is an option for some older patients with breast cancer

Related Stories

Avoiding radiotherapy is an option for some older patients with breast cancer

December 11, 2013
Omission of radiotherapy is a reasonable option for women age 65 or older who receive hormone therapy after breast-conserving surgery for hormone receptor-positive, axillary node-negative breast cancer, according to results ...

Study identifies highly effective treatment option for patients with HER2-positive breast cancer

December 11, 2013
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of ...

Researchers to present event-free and overall survival results from NeoALTTO trial

December 11, 2013
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented ...

High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab

December 11, 2013
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at ...

Study shows radiotherapy and surgery provide regional control for breast cancer patients

June 3, 2013
Final analysis of the EORTC 10981-22023 AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial has shown that both axillary lymph node dissection and axillary radiotherapy provide excellent regional control ...

Combined therapy linked to lower chance of recurrence in women with small, HER2+ breast cancers

December 11, 2013
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.